TCR2 Therapeutics Stock Plunges On Safety Signals From Gavo-cel Solid Tumor Trial

  • TCR2 Therapeutics Inc TCRR stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. 
  • The data will be at the European Society for Medical Oncology (ESMO21) Congress 2021.
  • Gavo-cel was administered up to dose level 5 (DL5) (5x108/m2 following lymphodepletion). 
  • Two dose-limiting toxicities were reported.
  • One Grade 3 pneumonitis at DL1, which was resolved with supportive measures, and dose escalation continued.
  • One Grade 5 bronchoalveolar hemorrhage at DL5, along with severe CRS in all three patients treated at this dose level was reported.
  •  The safety review team declared 5x108/m2 as the maximum tolerated dose. 
  • Six patients were evaluable for response. Tumor regression was observed in 15 (94%) patients with a disease control rate (DCR) of 81%. 
  • Six patients achieved partial responses (PRs) by target lesion assessment, four of whom achieved a PR. 
  • The objective response rate (ORR) was 31% by independent review assessment and 38% by investigator assessment.
  • Price Action: TCRR stock dropped 31.7% at $10.74 during the market session on the last check Friday.
  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareSmall CapMoversTrading IdeasGeneralBriefsESMO21Phase 1 TrialSolid Tumor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!